# Rifampin Injection: FDA shortage status

> FDA source status only. Nationwide status is not local pharmacy inventory. This page does not provide medical, treatment, substitution, or dosing advice.

- Derived status: current
- Source statuses: Current, To Be Discontinued
- FDA package records: 4
- Latest FDA row update: 08/20/2026
- Retrieved: 2026-08-22T15:54:11+00:00

## FDA package and manufacturer records

- Fresenius Kabi USA, LLC — Rifampin, Injection, 600 mg (NDC 63323-351-20) — FDA availability: Unavailable — updated: 08/04/2026
- Mylan Institutional, a Viatris Company — Rifampin, Injection, 600 mg (NDC 67457-445-60) — FDA availability: Unavailable — updated: 08/20/2026
- Sanofi-Aventis U.S. LLC — Rifadin, Injection, 600 mg (NDC 0068-0597-01) — FDA availability: Unavailable — updated: 06/22/2026
- Sanofi-Aventis U.S. LLC — Rifadin, Injection, 600 mg/10 mL (NDC 0068-0597-01) — FDA availability: Not stated — updated: 04/20/2026

## Sources and formats

- [FDA openFDA source](https://api.fda.gov/drug/shortages.json)
- [Canonical HTML](https://citefacts.com/shortages/rifampin-injection)
- [JSON record](https://citefacts.com/shortages/rifampin-injection.json)